InflaRx Shares In-Dept Analysis About Vilobelimab, Stock Down In Pre-Market
I'm PortAI, I can summarize articles.
InflaRx N.V. (IFRX) announced updates on its Phase 3 study for vilobelimab in pyoderma gangrenosum, which was terminated due to futility. An in-depth analysis shows vilobelimab's efficacy, particularly in ulcer volume reduction, with a 20.8% closure rate compared to 16.7% for placebo. Key secondary endpoints also favored vilobelimab. The company plans to meet with the FDA to discuss future steps. In pre-market trading, IFRX shares fell 3.93% to $0.97.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments